Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPK Inhibition to Restore Radioiodine Uptake in Thyroid Cancer (ERRITI)
NCT04619316Phase 2Unknown
- Sponsor
- Universitätsmedizin Essen
- Start
- Feb 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib and dabrafenib + trametinib in thyroid cancer, sponsored by Universitätsmedizin Essen. Status: unknown.
02
Drugs
trametinibdabrafenib + trametinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04619316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619316.